ArticleBiomedical reports2026
ALDH5A1 as a key in osteonecrosis of the femoral head: Insights from bioinformatics and experimental validation.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aims to identify key genes and elucidate the molecular mechanisms underlying osteonecrosis of the femoral head (ONFH), with the goal of discovering effective diagnostic and therapeutic targets. Microarray data were sourced from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were identified using the Limma method. Feature genes were selected through Support Vector Machine, Random Forest and Least Absolute Shrinkage and Selection Operator algorithms. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis. Functional enrichment and immune infiltration analyses were performed. Experimental validation included RT-qPCR, western blotting and immunofluorescence in ONFH bone tissue. Additionally, a competing endogenous RNA (ceRNA) network was constructed using Cytoscape (v3.10.1). A total of 51 DEGs were identified, comprising 33 downregulated and 18 upregulated genes. Aldehyde dehydrogenase 5 family member A1 (ALDH5A1) consistently emerged as a key gene across all machine learning models, demonstrating high diagnostic value according to ROC analysis. Enrichment analysis indicated that ALDH5A1-related DEGs were predominantly involved in 'Toll-like receptor signaling', 'RIG-like receptor signaling', 'Leishmania infection' and 'Cytosolic DNA sensing'. Immune analysis revealed associations between ONFH and HLA/MHC-I molecules, neutrophils and regulatory T cells, with ALDH5A1 showing a negative correlation with activated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.